Search

Displaying results 3621 - 3630 of 4334 in total
  1. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    Approximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel

  2. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after another ROS1 inhibitor has failed rather than as

  3. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    It was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998]

  4. Drug

    Malacidin A

    go.drugbank.com/drugs/DB14051
    Experimental

    Malacidin A, along with DB14052, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic ...

  5. Drug

    Malacidin B

    go.drugbank.com/drugs/DB14052
    Experimental

    Malacidin B, along with DB14051, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic ...

  6. Drug

    beta-Naphthoflavone

    go.drugbank.com/drugs/DB06732
    Experimental

    β-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs).

  7. Drug

    Canertinib

    go.drugbank.com/drugs/DB05424
    Investigational

    Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

  8. Drug

    Imgatuzumab

    go.drugbank.com/drugs/DB14884
    Investigational

    Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With

  9. Drug

    Alobresib

    go.drugbank.com/drugs/DB14970
    Investigational

    Alobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants

  10. Drug

    Deudextromethorphan

    go.drugbank.com/drugs/DB19054
    Investigational

    Deudextromethorphan is under investigation in clinical trial NCT02153502 (Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an